Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.
about
Elotuzumab for the treatment of multiple myelomaThe role of maintenance therapy in multiple myelomaTreatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumabElotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.Multiple myeloma in the marrow: pathogenesis and treatments.Immunologic approaches for the treatment of multiple myeloma.Elotuzumab: First Global Approval.Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.Emerging antibodies for the treatment of multiple myeloma.Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.Efficacy and safety of elotuzumab for the treatment of multiple myeloma.Integration of Novel Agents into the Care of Patients with Multiple Myeloma.Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.
P2860
Q26740278-A4E6ED14-80B2-4459-8FF6-7390A246BC32Q28071644-701F434A-A69E-4961-BEF5-E963492A3856Q28078993-6E068A95-517C-428F-B985-0D9BBFB241D1Q30249513-E37A9FC9-1BD9-41A2-9B96-C69885519AD1Q36725401-F25472AF-A392-4BF2-83A6-B2CAC2EAFC14Q38692244-138C7E5C-A6EE-4582-8123-B3483AADF295Q38711212-7E9C0E1B-67E9-4EBA-B22E-F0AEBA25570DQ38809499-00993B66-F737-4595-A4C6-89AC80E327AAQ38838239-E0CAACC3-E104-4FB8-B3A0-DB9701126E5BQ38929980-DC82642C-BB17-484C-88EC-1019700A6E97Q39070515-9633543B-1005-48FE-9449-D8901A48DE41Q46754093-63A818DE-43EC-4909-9B3F-A1B6CBEB3BCCQ55310350-6F8976FB-2265-4B85-9120-3DF45F05D9E2
P2860
Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Phase I safety data of lenalid ...... multiple myeloma: SWOG S1211.
@en
Phase I safety data of lenalid ...... multiple myeloma: SWOG S1211.
@nl
type
label
Phase I safety data of lenalid ...... multiple myeloma: SWOG S1211.
@en
Phase I safety data of lenalid ...... multiple myeloma: SWOG S1211.
@nl
prefLabel
Phase I safety data of lenalid ...... multiple myeloma: SWOG S1211.
@en
Phase I safety data of lenalid ...... multiple myeloma: SWOG S1211.
@nl
P2093
P2860
P356
P1433
P1476
Phase I safety data of lenalid ...... multiple myeloma: SWOG S1211.
@en
P2093
B Bartlett
J A Zonder
M Rosenzweig
R Z Orlowski
S Ailawadhi
P2860
P2888
P356
10.1038/BCJ.2015.62
P50
P577
2015-08-07T00:00:00Z
P5875
P6179
1029759233